Breast Cancer Clinical Trial

Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer

Summary

This randomized pilot clinical trial studies body warming in improving blood flow and oxygen delivery to tumors in patients with cancer. Heating tumor cells to several degrees above normal body temperature may kill tumor cells.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To determine the feasibility and efficacy of 2 different Body Warming to Alter (Thermo) Regulation and the Microenvironment (B-WARM) regimens on altering tumor blood flow in patients with a variety of malignancies.

SECONDARY OBJECTIVES:

I. To determine if duration and thermal dose of B-WARM changes duration and extent of tumor blood flow changes in patients with a variety of malignancies.

OUTLINE: Patients are randomized to 1of 2 arms.

ARM I: Patients undergo B-WARM at 39 degrees Celsius (C) for 30 minutes.

ARM II: Patients undergo B-WARM at 39 degrees C for 2 hours.

After completion of study, patients are followed up at 30 days.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with a variety of malignancies (i.e., melanoma, sarcoma, colon, head and neck, renal, breast, lung, ovary, liver)
Patients must have measurable disease (1.0 cm or greater) by computed tomography (CT) scan
Have an estimated glomerular filtration rate (eGFR) (using the Cockcroft-Gault equation) of more than 60 mL/min
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment
Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

History of prior myocardial infarction or arrhythmia
History of any condition deemed by the principal investigator to be a contraindication to B-WARM therapy (e.g., skin reaction, dysregulation of thermoregulation, etc)
All patients with transdermal patches (e.g.; fentanyl, Lidoderm, scopolamine, etc)
Pregnant or nursing female patients
Unwilling or unable to follow protocol requirements
Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive B-WARM
Received an investigational agent within 30 days prior to enrollment

Received any systemic therapy within 21 days prior to planned B-WARM therapy

Patients may be enrolled on study but at least 21 days should elapse prior to date of B-WARM therapy

Patients should not have either CT scanning or B-WARM if they have a fever at the time

Fever should be worked up and treated as appropriate
Patients should be afebrile for 24 hours prior to scanning or B-WARM therapy

Study is for people with:

Breast Cancer

Estimated Enrollment:

9

Study ID:

NCT01896778

Recruitment Status:

Completed

Sponsor:

Roswell Park Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Roswell Park Cancer Institute
Buffalo New York, 14263, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

9

Study ID:

NCT01896778

Recruitment Status:

Completed

Sponsor:


Roswell Park Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.